Interpreting the apparent benefit of thoracic radiotherapy in metastatic NSCLC: patient selection and analytical issues remain important-a comment on Xue et al.

Authors

Lili Qin, Shasha Wang, Haifeng Qin

Published in

Journal of cancer research and clinical oncology. Volume 152. Issue 7. Jul 27, 2026. Epub Jul 27, 2026.

Abstract

Thoracic radiotherapy (TRT) has been proposed as a potentially beneficial adjunct to first-line targeted therapy or chemoimmunotherapy in metastatic non-small cell lung cancer (NSCLC). This commentary discusses the retrospective study by Xue et al. and highlights several methodological issues that may influence interpretation of the reported survival benefit. Although the observed improvement in overall survival is clinically encouraging, imbalances in metastatic burden, inconsistent incorporation of key prognostic variables, and limited maturity of survival data may introduce residual confounding. Additional concerns include the causal interpretation of multivariable models, overlapping definitions of pulmonary toxicity, time-dependent adverse events, and unadjusted subgroup analyses. Overall, TRT may benefit carefully selected patients, but prospective studies and robust real-world analyses using causal-inference methods are needed to define optimal candidates and ensure safe implementation.

PMID:
42509512
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.